Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major
drawback of replacement therapy in persons with congenital hemophilia A (PwHA) …

In the treatment of hemophilia A, the 20%‐30% risk of developing of anti‐factor VIII (FVIII)
antibodies, or inhibitors, is the dominant concern among healthcare providers. Immune …

Background Transplacental delivery of maternal immunoglobulin G (IgG) provides humoral
protection during the first months of life until the newborn's immune system reaches maturity …

Von Willebrand factor (VWF) modulates factor VIII (FVIII) clearance and the anti-FVIII
immune response. Despite the high affinity that defines the FVIII/VWF interaction …

Abstract Efanesoctocog alfa (Altuviiio, TM Sanofi-SOBI) is a B domain-deleted single-chain
Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Its ingenious …

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood
coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate …

In humans, maternal IgGs are transferred to the fetus from the second trimester of pregnancy
onwards. The transplacental delivery of maternal IgG is mediated by its binding to the …

Essentials• Initial immune cell interactions leading to factor (F) VIII immunity are not well
characterized.• We assessed cellular interactions and expression profiles in hemophilia A …